WO1998000168A1 - Topical composition comprising a combination of antihistaminic compounds with terpenoid compounds - Google Patents
Topical composition comprising a combination of antihistaminic compounds with terpenoid compounds Download PDFInfo
- Publication number
- WO1998000168A1 WO1998000168A1 PCT/EP1997/003421 EP9703421W WO9800168A1 WO 1998000168 A1 WO1998000168 A1 WO 1998000168A1 EP 9703421 W EP9703421 W EP 9703421W WO 9800168 A1 WO9800168 A1 WO 9800168A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- acid
- antihistaminic
- terpenoid
- topically
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Definitions
- antihistaminic compounds for the treatment of skin diseases, such as pruritus or insect bites, is known in the art.
- the invention relates to the topical use of a topically applicable antihistaminic compound in combination with a terpenoid compound (for the manufacture of a topical medicament) for the treatment of allergic and inflammatory skin diseases.
- Allergic and inflammatory skin diseases are, for example, pruritus, insect bites, sunburn, others burns, urticaria, eczema, neurodermitis, atopic dermatitis or contact dermatitis.
- ahistan etymemazine, fenethazine, N-hydroxyethylpromethazine chloride, isopromethazine, mequitazine, methdilazine, promethazine, pyrathiazine, thiazinamium methylsulfate or trimeprazine;
- a tricyclic other than phenothiazines e.g. azatadine, clobenzepam, cyproheptadine, deptropine, isothipendyl, loratadine or prothipendyl; and
- an antihistaminic compound of another structure e.g.
- antazoline astemizole, azelastine, cetoxime, clemizole, clobenztropine, diphenazoline, diphenhydramine, ebastine, emedastine, levocabastine, mebhydroline, phenindamine, terfenadine or tritoqualine.
- topically applicable antihistaminic compound is to be understood as also to include (1 ) any topically acceptable salt of a free compound (acid or base) mentioned above, (2) any free compound (acid or base) or any other topically acceptable salt of a salt mentioned above, and (3) any active metabolite of a compound mentioned above.
- active metabolites are carebastine, which is the active metabolite of ebastine; norastemizole, which is the active metabolite of astemizole, or terfenadine carboxilate, which is the active metabolite of terfenadine.
- a topically acceptable salt of an antihistaminic compound having a basic group is e.g. an acid addition salt.
- Suitable acid components may be, for example, strong inorganic acids, typically mineral acids, e.g. sulfuric acid, phosphoric acids, e.g. orthophosphoric acid, hydrohalic acids, e.g. hydrochloric acid, or strong organic carboxylic acids, typically lower alkanecarboxylic acids which may be substituted, e.g. by halogen, such as acetic acid or trifluoroacetic acid, dicarboxylic acids which may be unsaturated, e.g.
- a topically acceptable salt of an antihistaminic compound having an acidic group is e.g. an alkali metal or alkaline earth metal salt, e.g. the sodium, potassium, magnesium or calcium salt, an aluminium salt or a transition metal salt, e.g. the zinc or copper salt, or a corresponding salt with ammonia or organic amines.
- Organic amines that come into consideration are, for example, the following: alkylamines, such as mono-, di- or tri-lower alkylamines, e.g.
- alkyienediamines such as lower alkylenediamines, e.g. ethylenediamine, alkylamines substituted by phenyl, such as mono- or di-phenyl-lower alkylamines, e.g. benzylamine or 1- or 2-phenylethylamine, hydroxy-alkylamines, such as mono-, di- or tri-hydroxy-lower alkylamines, e.g.
- alkyl-di-lower alkylamines e.g. N,N-dimethylamino- or N,N-diethylamino- ethanol
- amino sugars such as those in which the amino group is optionally substituted by at least one lower alkyl group, e.g.
- D-glucosamine, D-galactosamine or marmosamine derived from monosaccharides in which an alcoholic hydroxy group is replaced by an amino group
- N-methyl-D-glucosamine an N-lower alkylated amino sugar
- cycloalkylamines such as mono- or di-cycloalkylamines, e.g. cyclohexylamine or dicyclohexylamine, basic amino acids, e.g. arginine, histidine, lysine or ornithine, or cyclic amines, such as lower alkyleneamines or lower alkenyleneamines, e.g.
- pyrrolidine 1-ethyl-pyrrolidine, 2-hydroxyethyl-pyrrolidine, piperidine, 1-ethyl-piperidine, 2-hydroxyethyl- piperidine or pyrroline, or lower alkyleneamines or lower alkenyleneamines in which the carbon chain is interrupted by aza (-NH-), N-lower alkylaza [-N(-lower alkyl)-], oxa (-O-) and/or thia (-S-), e.g. imidazoline, 3-methylimidazoline, piperazine, 4-methyl- or 4- ethylpiperazine, morpholine or thiomorpholine.
- Preferred antihistaminic compounds are acrivastine, brompheniramine, chlorpheniramine.. dexchlorpheniramine, dimethindene, triprolidine; bromodiphenhydramine, clemastine, phenyltoloxamine, piprinhydrinate, pyrilamine, tripelennamine, cetirizine, hydroxyzine; methdilazine, promethazine, trimeprazine, azatadine, cyproheptadine, loratadine, astemizole, diphenhydramine, levocabastine and terfenadine, or topically acceptable salts thereof.
- antihistaminic compounds are dimethindene and clemastine, or a topically acceptable salt thereof, e.g. dimethindene maleate or clemastine hydrogen fumarate.
- a terpenoid compound is, for example, a monoterpenoid compound, a diterpenoid compound, a triterpenoid compound or a sesquiterpenoid compound.
- a monoterpenoid compound is e.g. camphor, 3-carene, carvacrol, carvone, chrysanthemic acid; cineol, e.g. 1 ,8-cineol; gefarnate, geraniol, linalool, limonene, menthol, pulegone, thujone or thymol.
- a diterpenoid compound is e.g. aphidicolin, forskolin, phytanic acid or phytol.
- a triterpenoid compound is, for example, glycyrrhetinic acid or a sapogenin, e.g. oleanolic acid or diosgenin.
- a sesquiterpenoid compound is e.g. farnesol or santonin.
- terpenoid compound is intended also to cover any derivative and any topically acceptable salt of a terpenoid compound.
- a carboxylic acid is, for example, a C C 7 -aliphatic, a cycloaliphatic, an aromatic, an aromatic-C ⁇ -C 7 -aliphatic, a heteroaromatic or a heteroaromatic-C ⁇ -C 7 -aliphatic carboxylic acid, which carboxylic acid may be unsubstituted or substituted, for example by one or more substituents selected from hydroxy, halogen, C- * -C 7 -alkoxy, carboxy, C ⁇ -C 7 -alkoxycarbonyl, cyano, amino, CrC 7 -alkylamino, di-CrC-r-alkylamino, C ⁇ -C 7 -alkanoylamino, nitro, C ⁇ -C 7 -alkyl and halogen-C C 7 -alkyl (e.g.trifluoromethyl).
- substituents selected from hydroxy, halogen, C- * -C 7 -alkoxy, carboxy,
- a carboxylic acid is a C 1 -C 7 - alkanoic acid which is unsubstituted or substituted by hydroxy, halogen, carboxy or amino, a C 3 -C 7 -cycloalkanoic acid; a phenyl-C,-C 7 -alkanoic acid, a benzoic acid or a naphthoic acid in each of which the phenyl ring(s) may be unsubstituted or substituted by one or more substituents selected from d-C 7 -alkyl, halogen-CrC -alkyl, hydroxy, halogen, CrC 7 -alkoxy, carboxy, C C 7 -alkoxycarbonyl, cyano, amino, C ⁇ -C 7 -alkylamino, di-d-C-V-alkylamino, C ⁇ -C - alkanoylamino and nitro; or a heteroaromatic carboxylic acid or a
- a carboxylic acid is a d-C 7 -alkanoic acid which is unsubstituted or substituted by hydroxy.
- Preferred terpenoid compounds are menthol, menthol esters, especially menthyl lactate, or cineol, more preferably menthol or menthyl lactate, and in one embodiment menthol, and in another embodiment menthyl lactate.
- menthyl lactate The structural formula of menthyl lactate is as follows:
- racemate As the compound contains 4 asymmetric carbon atoms, there are existing 16 different stereoisomers.
- the term “menthyl lactate” is intended to cover each of these stereoisomers as well as any racemates and any other mixtures of these stereoisomers. Preferred is the racemate of the following structure
- the combination according to the invention can be applied, usually in the form of a topical pharmaceutical composition, to any portion of the skin.
- application to the external genitalia, or the eyelids, or lips is not suggested, recommended, or usually desired.
- a topical pharmaceutical composition for topical administration the antiallergic and anti inflammatory efficacy of the combination is enhanced in an unexpected manner.
- the antihistaminic compound and the terpenoid compound both act as topical antiinflammatory agents but have different mechanisms of action and therefore act complementarily.
- the topical compositions of the invention are characterised by an extremely good skin permeation of the drugs applied.
- the topical pharmaceutical compositions of the invention have valuable pharmacological properties. Especially they are beneficial in the treatment of allergic and inflammatory skin diseases including atopic dermatitis.
- compositions of the invention are confirmed by classical toxicological studies, such as the acute toxicity mice test, the acute rabbit skin/eye irritation test or sensitization tests. Adverse effects, such as rough skin or skin irritation, are not observed.
- the invention relates to the use of a mixture of an antihistaminic compound with a terpenoid compound, in which mixture the antihistaminic compound is present in an amount of from 0.01 up to 15%, and the terpenoid compound is present in an amount of from 0.1 up to 15%, especially of from 0.1 up to 10%, very especially of from 0.5 up to 10%, more especially of from 0.5 up to 8%, most especially of from 1 up to 8%, advantageously of from 2 up to 8%, in particular of from 3 up to 8%, and first and foremost of from 4 up to 8%; further of from 3 up to 10%.
- the combination of an antihistaminic compound and a terpenoid compound is used in the form of a topical pharmaceutical composition which is also an object of the present invention.
- the invention further relates to a topical pharmaceutical composition
- a topical pharmaceutical composition comprising at least one topically applicable antihistaminic compound and at least one terpenoid compound together with at least one topically acceptable carrier material.
- the topically administered pharmaceutical compositions according to the invention comprise both the topically applicable antihistaminic compound(s) and the terpenoid compound in pharmacologically effective amounts.
- the daily dosage of the active ingredients depends on age and individual condition and on the mode of administration.
- the topical pharmaceutical compositions for example in the form of emulsion-gels, creams or ointments, may be applied once, twice or three times daily. But also more frequent daily applications are possible: such can provide a continual therapy which may lead to an even more rapid improvement of the conditions treated..
- Patches and bandages may be applied, for example, once daily or only once, twice or three times a week.
- a topical composition of the invention - as well in a mixture used according to the invention - the antihistaminic compound(s) is (are) e.g. present in an amount of from 0.01 up to 15%, especially of from 0.02 up to 5%, and in particular of from 0.02 up to 2.5%, of the total composition.
- the terpenoid compound is present in an amount of from 0.1 up to 15%, especially of from 0.1 up to 10%, very especially of from 0.5 up to 10%, more especially of from 0.5 up to 8%, most especially of from 1 up to 8%, advantageously of from 2 up to 8%, in particular of from 3 up to 8%, and first and foremost of from 4 up to 8%; further of from 3 up to 10%.
- the dosage of the active ingredients may depend on various factors, such as warmblooded species, sex, age, weight and individual condition of the warm-blooded animal.
- the invention relates to a method of treating allergic and inflammatory skin diseases which comprises topically administering to a mammal in need of such treatment a therapeutically effective amount of at least one antihistaminic compound together with a therapeutically effective amount of at least one terpenoid compound.
- compositions suitable for topical administration are e.g. creams, lotions, ointments, microemulsions, fatty ointments, gels, emulsion-gels, pastes, foams, tinctures, solutions, patches, bandages and transdermal therapeutic systems; preferred are emulsion- gels, gels, creams, lotions, solutions, patches and bandages.
- Creams or lotions are oil-in-water emulsions.
- oily base there are used especially fatty alcohols, especially those containing from 12 to 18 carbon atoms, for example lauryl, cetyl or stearyl alcohol, fatty acids, especially those containing from 10 to 18 carbon atoms, for example palmitic or stearic acid, fatty acid esters, e.g. glyceryl tricaprilocaprate (neutral oil) or cetyl palmitate, liquid to solid waxes, for example isopropyl myristate, wool wax or beeswax, and/or hydrocarbons, especially liquid, semi-solid or solid substances or mixtures thereof, for example petroleum jelly (petrolatum) or paraffin oil.
- fatty alcohols especially those containing from 12 to 18 carbon atoms, for example lauryl, cetyl or stearyl alcohol
- fatty acids especially those containing from 10 to 18 carbon atoms, for example palmitic or stearic acid
- Suitable emulsifiers are surface-active substances having predominantly hydrophilic properties, such as corresponding non-ionic emulsifiers, for example fatty acid esters of polyalcohols and/or ethylene oxide adducts thereof, especially corresponding fatty acid esters with (poly)ethylene glycol, (poly)propylene glycol or sorbitol, the fatty acid moiety containing especially from 10 to 18 carbon atoms, especially partial glycerol fatty acid esters or partial fatty acid esters of polyhydroxyethylene sorbitan, such as polyglycerol fatty acid esters or polyoxyethylene sorbitan fatty acid esters (Tweens), and also polyoxyethylene fatty alcohol ethers or fatty acid esters, the fatty alcohol moiety containing especially from 12 to 18 carbon atoms and the fatty acid moiety especially from 10 to 18 carbon atoms, such as polyhydroxyethylenecetylstearyl ether (for example Cetomacrogol 1000) or polyhydroxy- ethyleneg
- Additives to the aqueous phase are, inter alia, agents that prevent the creams from drying out, for example humectants, such as polyalcohols, such as glycerol, sorbitol, propylene glycol and/or polyethylene glycols, and also preservatives, perfumes, gelling agents, etc..
- humectants such as polyalcohols, such as glycerol, sorbitol, propylene glycol and/or polyethylene glycols, and also preservatives, perfumes, gelling agents, etc.
- Ointments are water-in-oil emulsions that contain up to 70%, but preferably from approximately 20% to approximately 50%, water or aqueous phase.
- Suitable as fatty phase are especially hydrocarbons, for example petroleum jelly, paraffin oil and/or hard paraffins, which, in order to improve the water-binding capacity, preferably contain suitable hydroxy compounds, such as fatty alcohols or esters thereof, for example cetyl alcohol or wool wax alcohols, or wool wax or beeswax.
- Emulsifiers are corresponding lipophilic substances, for example of the type indicated above, such as sorbitan fatty acid esters (Spans), for example sorbitan oleate and/or sorbitan isostearate.
- Additives to the aqueous phase are, inter alia, humectants, such as polyalcohols, for example glycerol, propylene glycol, sorbitol and/or polyethylene glycol, and also preservatives, perfumes, etc.
- humectants such as polyalcohols, for example glycerol, propylene glycol, sorbitol and/or polyethylene glycol, and also preservatives, perfumes, etc.
- Microemulsions are isotropic systems based on the following four components: water, a surfactant, for example a tensioactive, a lipid, such as a non-polar or polar oil, for example paraffin oil, and an alcohol or polyalcohol containing lipophilic groups, for example 2- octyldodecanol or ethoxalated glycerol or polyglycerol esters.
- a surfactant for example a tensioactive
- a lipid such as a non-polar or polar oil, for example paraffin oil
- an alcohol or polyalcohol containing lipophilic groups for example 2- octyldodecanol or ethoxalated glycerol or polyglycerol esters.
- other additives may be added to the microemulsions.
- Fatty ointments are water-free and contain as base especially hydrocarbons, for example paraffin, petroleum jelly and/or liquid paraffins, also natural or partially synthetic fat, such as fatty acid esters of glycerol, for example coconut fatty acid triglyceride, or preferably hardened oils, for example hydrogenated groundnut oil, castor oil or waxes, also fatty acid partial esters of glycerol, for example glycerol mono- and di-stearate, and also, for example, the fatty alcohols increasing the water-absorption capacity, emulsifiers and/or additives mentioned in connection with the ointments.
- hydrocarbons for example paraffin, petroleum jelly and/or liquid paraffins
- natural or partially synthetic fat such as fatty acid esters of glycerol, for example coconut fatty acid triglyceride, or preferably hardened oils, for example hydrogenated groundnut oil, castor oil or waxes, also fatty acid partial esters of glycerol,
- aqueous gels water-free gels and gels having a low water content, which gels consist of swellable, gel-forming materials.
- gels consist of swellable, gel-forming materials.
- transparent hydrogels based on inorganic or organic macromolecules.
- High molecular weight inorganic components having gel-forming properties are predominantly water-containing silicates, such as aluminium silicates, for example bentonite, magnesium aluminium silicates, for example Veegum, or colloidal silicic acid, for example Aerosil.
- high molecular weight organic substances there are used, for example, natural, semi- synthetic or synthetic macromolecules.
- Natural and semi-synthetic polymers are derived, for example, from polysaccharides containing a great variety of carbohydrate components, such as celluloses, starches, tragacanth, gum arabic and agar-agar, and gelatin, alginic acid and salts thereof, for example sodium alginate, and derivatives thereof, such as lower alkylcelluloses, for example methyl- or ethyl-cellulose, carboxy- or hydroxy-lower alkylcelluloses, for example carboxymethyl-or hydroxyethyl-cellulose.
- the components of synthetic gel-forming macromolecules are, for example, suitably substituted unsaturated aliphatic compounds such as vinyl alcohol, vinylpyrrolidine, acrylic or methacrylic acid.
- polymers examples include polyvinyl alcohol derivatives, such as polyviol, polyvinylpyrrolidines, such as collidone, polyacrylates and polymethacrylates, especially having a molecular weight of from approximately 80000 to approximately 1 million, or salts thereof, such as Rohagit S, Eudispert or Carbopol (Carbomer).
- Customary additives such as preservatives, humectants or perfumes, may be added to the gels.
- Emulsion-gels - also called “emulgels” - represent topical compositions which combine the properties of a gel with those of an oil-in-water emulsion. In contrast to gels, they contain a lipid phase which due to its fat-restoring properties enables the formulation to be massaged in whilst, at the same time, the direct absorption into the skin is experienced as a pleasant property. Furthermore, one can observe an increased solubility for lipophilic active ingredients.
- One advantage of emulsion-gels over oil-in-water emulsions resides in the enhanced cooling effect which is brought about by the coldness due to evaporation of the additional alcohol component, if present. Furthermore, one can observe an improved solubility of polar active ingredients.
- Foams are administered, for example, from pressurised containers and are liquid oil-in- water emulsions in aerosol form; unsubstituted hydrocarbons, such as alkanes, for example propane and/or butane, are used as propellant.
- hydrocarbons for example paraffin oil, fatty alcohols, for example cetyl alcohol, fatty acid esters, for example isopropyl myristate, and/or other waxes.
- emulsifiers there are used, inter alia, mixtures of emulsifiers having predominantly hydrophilic properties, such as polyoxyethylene sorbitan fatty acid esters (Tweens), and emulsifiers having predominantly lipophilic properties, such as sorbitan fatty acid esters (Spans).
- Teweens polyoxyethylene sorbitan fatty acid esters
- Spans sorbitan fatty acid esters
- the customary additives such as preservatives, etc., are also added.
- Tinctures and solutions generally have an ethanolic base, to which water may be added and to which there are added, inter alia, polyalcohols, for example glycerol, glycols and/or polyethylene glycol, as humectants for reducing evaporation, and fat-restoring substances, such as fatty acid esters with low molecular weight polyethylene glycols, propylene glycol or glycerol, that is to say lipophilic substances that are soluble in the aqueous mixture, as a replacement for the fatty substances removed from the skin by the ethanol, and, if necessary, other adjuncts and additives.
- Suitable tinctures or solutions may also be applied in spray form by means of suitable devices.
- Transdermal therapeutic systems with - in particular - local delivery of the active substances contain an effective amount of each of the active ingredients optionally together with a carrier:
- Useful carriers comprise absorbable pharmacological suitable solvents to assist passage of the active ingredients through the skin.
- the matrix (b) is normally present as a mixture of all components or may consist of separate layers.
- topically administrable pharmaceutical preparations are effected in a manner known p_er se, for example by dissolving or suspending the active ingredients in the base or, if necessary, in a portion thereof.
- active ingredients are administered in the form of a solution, they are generally dissolved in one of the two phases before emulsification.
- Example 1 An emulsion-gel containing the maleate salt of dimethindene and menthyl lactate is manufactured as follows.
- the acrylic acid polymerisate is dispersed in a portion of water by means of a rotor-stator homogeniser (for example Homorex*).
- a rotor-stator homogeniser for example Homorex*.
- a solution of the maleate salt of dimethindene, diethylamine, sodium sulphite and polyethylene glycol 300 in isopropanol and the remaining water is added thereto and distributed homogeneously.
- To form the fatty phase the polyhydroxyethylene cetyl stearyl ether, Mygliol* 812 and the paraffin oil are melted together at 75°. Menthyl lactate is added to the fatty phase, and then the whole fatty phase is slowly added to the previously formed gel and emulsified.
- Example 2 An emulsion-gel containing the maleate salt of dimethindene and menthyl lactate is manufactured as follows.
- the acrylic acid polymerisate is dispersed in a portion of water by means of a rotor-stator homogeniser (for example Homorex ® ).
- a rotor-stator homogeniser for example Homorex ®
- a solution of dimethindene maleate, NaOH, butylhydroxytoluene, disodium edetate and benzalkonium chloride in a mixture of propylene glycol/water is added thereto and distributed homogeneously.
- the polyhydroxyethylene cetyl stearyl ether, Mygliol* 812, the paraffin oil and benzyl alcohol are melted together at 75°.
- the menthyl lactate is added to the fatty phase, and then the whole fatty phase is slowly added to the previously formed gel and emulsified.
- Example 3 An emulsion-gel containing the maleate salt of dimethindene and l-menthol has the following composition and is manufactured in analogy to the examples 1 and 2.
- Example 4 A lotion containing the maleate salt of dimethindene and menthyl lactate has the following composition and is manufactured in analogy to the examples 1 and 2.
- Example 5 An emulsion-gel containing clemastine hydrogen fumarate and menthyl lactate is manufactured as follows.
- the acrylic acid polymerisate is dispersed in a portion of water by means of a rotor-stator homogeniser (for example Homorex*).
- a rotor-stator homogeniser for example Homorex*.
- a solution of clemastine hydrogen fumarate, diethylamine, sodium sulphite and polyethylene glycol 300 in isopropanol and the remaining water is added thereto and distributed homogeneously.
- the polyhydroxyethylene cetyl stearyl ether, Mygliol* 812 and the paraffin oil are melted together at 75°. Menthyl lactate is added to the fatty phase, and then the whole fatty phase is slowly added to the previously formed gel and emulsified.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97930461A EP0910410A1 (en) | 1996-07-02 | 1997-07-01 | Topical composition comprising a combination of antihistaminic compounds with terpenoid compounds |
AU34406/97A AU3440697A (en) | 1996-07-02 | 1997-07-01 | Topical composition comprising a combination of antihistaminic compounds with terpenoid compounds |
JP10503845A JP2000515498A (ja) | 1996-07-02 | 1997-07-01 | 抗ヒスタミン化合物とテルペノイド化合物の組み合わせからなる局所組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE96810436.4 | 1996-07-02 | ||
EP96810436 | 1996-07-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998000168A1 true WO1998000168A1 (en) | 1998-01-08 |
Family
ID=8225640
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1997/003421 WO1998000168A1 (en) | 1996-07-02 | 1997-07-01 | Topical composition comprising a combination of antihistaminic compounds with terpenoid compounds |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0910410A1 (tr) |
JP (1) | JP2000515498A (tr) |
AU (1) | AU3440697A (tr) |
CA (1) | CA2258513A1 (tr) |
TR (1) | TR199802769T2 (tr) |
WO (1) | WO1998000168A1 (tr) |
ZA (1) | ZA975902B (tr) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1050300A2 (en) * | 1999-04-22 | 2000-11-08 | Shiseido Company Limited | Selective antibacterial composition |
US6284802B1 (en) | 1999-04-19 | 2001-09-04 | The Procter & Gamble Company | Methods for regulating the condition of mammalian keratinous tissue |
WO2001085126A2 (en) * | 2000-05-09 | 2001-11-15 | Unilever Plc | Cosmetic skin care compositions containing pulegone |
JP2002512029A (ja) * | 1998-04-21 | 2002-04-23 | マックス−プランク−ゲゼルシャフト ツール フォルデルング デル ヴィッセンシャフテン エー.ファウ. | ヒトk+イオンチャンネルおよびその治療的適用 |
WO2002045718A1 (en) * | 2000-12-08 | 2002-06-13 | Institut Pasteur De Lille | Use of active compounds capable of modulating the intracellular pathway triggered by the dp receptor in langerhans cells |
JP2002519366A (ja) * | 1998-07-07 | 2002-07-02 | トランスダーマル・テクノロジーズ・インコーポレーテツド | 医薬的に活性な作用物質を迅速かつ非刺激的に経皮送達するための組成物、およびそのような組成物の調剤法およびそれらの送達 |
WO2002096870A2 (en) * | 2001-05-31 | 2002-12-05 | The Regents Of The University Of California | Sponge-derived terpenoids and methods of use |
US6720423B2 (en) | 2002-04-30 | 2004-04-13 | Allergan, Inc. | Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors |
WO2004110396A1 (de) * | 2003-06-17 | 2004-12-23 | Dsm Ip Assets B.V. | Topisches mittel enthaltend phytansäure oder ein derivat davon |
WO2006015861A2 (en) * | 2004-08-11 | 2006-02-16 | Novartis Ag | Drop preparations comprising dimetindene |
EP1804761A2 (en) * | 2004-09-13 | 2007-07-11 | Cynthia A. Boxrud | Compositions and methods for treatment of skin discoloration |
WO2007110380A1 (en) * | 2006-03-25 | 2007-10-04 | Boehringer Ingelheim International Gmbh | Insect bite relief preparation comprising epinastine |
WO2009070431A1 (en) * | 2007-11-27 | 2009-06-04 | Harry Dugger | Antihistamine/corticosteroid preparations for the treatment of atopic dermatitis |
EP2735309A1 (en) | 2012-11-27 | 2014-05-28 | Eduardo Cos Alfonso | Pharmaceutical composition for the treatment of calcific tendinitis and/or calcific bursitis |
WO2018063876A1 (en) * | 2016-09-30 | 2018-04-05 | Alpha To Omega Pharmaceutical Consultants, Inc. | Transdermal and/or topical delivery systems comprising cetirizine dihydrochloride |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4614638B2 (ja) * | 2002-06-07 | 2011-01-19 | 第一三共株式会社 | 鎮痛剤組成物 |
EP1946753A4 (en) * | 2005-10-21 | 2009-05-13 | Medrx Co Ltd | PREPARATION FOR EXTERNAL APPLICATION COMPRISING A SALT OF A MASTOCYTE DEGRANULATION INHIBITOR COMPRISING A CARBOXYL GROUP WITH AN ORGANIC AMINE |
CN101390830B (zh) * | 2008-11-12 | 2011-05-18 | 常州市第四制药厂有限公司 | 一种盐酸赛庚啶乳膏剂及其制备方法 |
JP5912238B2 (ja) * | 2010-09-30 | 2016-04-27 | 小林製薬株式会社 | 乳化組成物 |
CA2899250C (en) * | 2013-02-01 | 2021-11-23 | Ddrops Company | Liquid menthol compositions |
JP6537775B2 (ja) * | 2014-03-10 | 2019-07-03 | 小林製薬株式会社 | 乳化組成物 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59122420A (ja) * | 1982-12-28 | 1984-07-14 | Otsuka Pharmaceut Factory Inc | 局所軟膏剤 |
EP0158090A1 (de) * | 1984-03-07 | 1985-10-16 | Roshdy Dr. Ismail | Mittel zur Behandlung und zum Schutz der Haut |
JPS62205019A (ja) * | 1986-03-03 | 1987-09-09 | Kao Corp | 外用医薬品組成物 |
EP0315079A1 (en) * | 1987-10-28 | 1989-05-10 | Nippon Shinyaku Company, Limited | Drug carriers |
WO1989012626A1 (en) * | 1988-06-24 | 1989-12-28 | Stephen Herman | Ozonides of terpenes and their medical uses |
WO1991012010A1 (en) * | 1990-02-12 | 1991-08-22 | Dermatologic Research Corporation | Treatment of pruritis with esters and amides |
JPH04154719A (ja) * | 1990-10-19 | 1992-05-27 | Hiroshi Kikuchi | 水虫薬 |
WO1992013540A1 (fr) * | 1991-02-06 | 1992-08-20 | Guy Parent | Onguent antalgique |
JPH05286860A (ja) * | 1992-04-03 | 1993-11-02 | Kowa Co | ゲル軟膏剤 |
WO1994008550A1 (en) * | 1992-10-09 | 1994-04-28 | The Procter & Gamble Company | Anaesthetic compositions |
-
1997
- 1997-07-01 JP JP10503845A patent/JP2000515498A/ja active Pending
- 1997-07-01 WO PCT/EP1997/003421 patent/WO1998000168A1/en not_active Application Discontinuation
- 1997-07-01 TR TR1998/02769T patent/TR199802769T2/tr unknown
- 1997-07-01 CA CA002258513A patent/CA2258513A1/en not_active Abandoned
- 1997-07-01 AU AU34406/97A patent/AU3440697A/en not_active Abandoned
- 1997-07-01 EP EP97930461A patent/EP0910410A1/en not_active Withdrawn
- 1997-07-02 ZA ZA975902A patent/ZA975902B/xx unknown
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59122420A (ja) * | 1982-12-28 | 1984-07-14 | Otsuka Pharmaceut Factory Inc | 局所軟膏剤 |
EP0158090A1 (de) * | 1984-03-07 | 1985-10-16 | Roshdy Dr. Ismail | Mittel zur Behandlung und zum Schutz der Haut |
JPS62205019A (ja) * | 1986-03-03 | 1987-09-09 | Kao Corp | 外用医薬品組成物 |
EP0315079A1 (en) * | 1987-10-28 | 1989-05-10 | Nippon Shinyaku Company, Limited | Drug carriers |
WO1989012626A1 (en) * | 1988-06-24 | 1989-12-28 | Stephen Herman | Ozonides of terpenes and their medical uses |
WO1991012010A1 (en) * | 1990-02-12 | 1991-08-22 | Dermatologic Research Corporation | Treatment of pruritis with esters and amides |
JPH04154719A (ja) * | 1990-10-19 | 1992-05-27 | Hiroshi Kikuchi | 水虫薬 |
WO1992013540A1 (fr) * | 1991-02-06 | 1992-08-20 | Guy Parent | Onguent antalgique |
JPH05286860A (ja) * | 1992-04-03 | 1993-11-02 | Kowa Co | ゲル軟膏剤 |
WO1994008550A1 (en) * | 1992-10-09 | 1994-04-28 | The Procter & Gamble Company | Anaesthetic compositions |
Non-Patent Citations (4)
Title |
---|
DATABASE WPI Week 9228, Derwent World Patents Index; AN 92-230523, XP002021801 * |
DATABASE WPI Week 9348, Derwent World Patents Index; AN 93-383002, XP002021800 * |
PATENT ABSTRACTS OF JAPAN vol. 008, no. 241 (C - 250) 6 November 1984 (1984-11-06) * |
PATENT ABSTRACTS OF JAPAN vol. 012, no. 059 (C - 478) 23 February 1988 (1988-02-23) * |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002512029A (ja) * | 1998-04-21 | 2002-04-23 | マックス−プランク−ゲゼルシャフト ツール フォルデルング デル ヴィッセンシャフテン エー.ファウ. | ヒトk+イオンチャンネルおよびその治療的適用 |
JP2002519366A (ja) * | 1998-07-07 | 2002-07-02 | トランスダーマル・テクノロジーズ・インコーポレーテツド | 医薬的に活性な作用物質を迅速かつ非刺激的に経皮送達するための組成物、およびそのような組成物の調剤法およびそれらの送達 |
US6284802B1 (en) | 1999-04-19 | 2001-09-04 | The Procter & Gamble Company | Methods for regulating the condition of mammalian keratinous tissue |
EP1050300A3 (en) * | 1999-04-22 | 2000-11-22 | Shiseido Company Limited | Selective antibacterial composition |
KR100454036B1 (ko) * | 1999-04-22 | 2004-10-26 | 가부시키가이샤 시세이도 | 선택적 항균 조성물 |
US6328984B1 (en) | 1999-04-22 | 2001-12-11 | Shiseido Co., Ltd. | Selective antibacterial composition |
EP1050300A2 (en) * | 1999-04-22 | 2000-11-08 | Shiseido Company Limited | Selective antibacterial composition |
WO2001085126A2 (en) * | 2000-05-09 | 2001-11-15 | Unilever Plc | Cosmetic skin care compositions containing pulegone |
WO2001085126A3 (en) * | 2000-05-09 | 2002-06-20 | Unilever Plc | Cosmetic skin care compositions containing pulegone |
US6391324B2 (en) * | 2000-05-09 | 2002-05-21 | Unilever Home & Personal Care Usa, Division Of Conopco | Cosmetic skin care compositions containing pulegone |
WO2002045718A1 (en) * | 2000-12-08 | 2002-06-13 | Institut Pasteur De Lille | Use of active compounds capable of modulating the intracellular pathway triggered by the dp receptor in langerhans cells |
WO2002096870A2 (en) * | 2001-05-31 | 2002-12-05 | The Regents Of The University Of California | Sponge-derived terpenoids and methods of use |
WO2002096870A3 (en) * | 2001-05-31 | 2003-08-07 | Univ California | Sponge-derived terpenoids and methods of use |
US6750247B2 (en) | 2001-05-31 | 2004-06-15 | Galileo Laboratories, Inc. | Sponge-derived terpenoids and methods of use |
US6720423B2 (en) | 2002-04-30 | 2004-04-13 | Allergan, Inc. | Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors |
WO2004110396A1 (de) * | 2003-06-17 | 2004-12-23 | Dsm Ip Assets B.V. | Topisches mittel enthaltend phytansäure oder ein derivat davon |
CN1809330B (zh) * | 2003-06-17 | 2010-10-13 | Dsmip资产公司 | 含有植烷酸或其衍生物的局部用制剂 |
WO2006015861A2 (en) * | 2004-08-11 | 2006-02-16 | Novartis Ag | Drop preparations comprising dimetindene |
WO2006015861A3 (en) * | 2004-08-11 | 2006-09-28 | Novartis Consumer Health Sa | Drop preparations comprising dimetindene |
EP1804761A2 (en) * | 2004-09-13 | 2007-07-11 | Cynthia A. Boxrud | Compositions and methods for treatment of skin discoloration |
EP1804761A4 (en) * | 2004-09-13 | 2008-09-17 | Evera Lab Llc | COMPOSITIONS AND METHODS OF TREATING SKIN DISORDER |
WO2007110380A1 (en) * | 2006-03-25 | 2007-10-04 | Boehringer Ingelheim International Gmbh | Insect bite relief preparation comprising epinastine |
WO2009070431A1 (en) * | 2007-11-27 | 2009-06-04 | Harry Dugger | Antihistamine/corticosteroid preparations for the treatment of atopic dermatitis |
EP2735309A1 (en) | 2012-11-27 | 2014-05-28 | Eduardo Cos Alfonso | Pharmaceutical composition for the treatment of calcific tendinitis and/or calcific bursitis |
WO2018063876A1 (en) * | 2016-09-30 | 2018-04-05 | Alpha To Omega Pharmaceutical Consultants, Inc. | Transdermal and/or topical delivery systems comprising cetirizine dihydrochloride |
Also Published As
Publication number | Publication date |
---|---|
CA2258513A1 (en) | 1998-01-08 |
JP2000515498A (ja) | 2000-11-21 |
TR199802769T2 (tr) | 1999-04-21 |
ZA975902B (en) | 1999-01-04 |
EP0910410A1 (en) | 1999-04-28 |
AU3440697A (en) | 1998-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998000168A1 (en) | Topical composition comprising a combination of antihistaminic compounds with terpenoid compounds | |
EP2714008B1 (en) | Pharmaceutical composition for administration to nails | |
CA2549505C (en) | Oleaginous pharmaceutical and cosmetic foam | |
EP0782855B1 (en) | Nimesulide for external use | |
JP4004182B2 (ja) | 乳化組成物 | |
US20050137164A1 (en) | Diclofenac compositions for the treatment of skin disorders | |
EP2135622B1 (en) | Compositions for providing an analgesic effect to the skin | |
JP2010529175A (ja) | マラセチア属酵母に対して抗真菌活性を有するテルペン | |
BR112021000183A2 (pt) | preparação medicinal para uso externo | |
WO1997042944A1 (en) | Topical composition | |
US4160844A (en) | Composition for treating skin mast cells and/or delayed cellular hypersensitivity reactions | |
AU651619B2 (en) | Topical treatment and composition | |
KR0138121B1 (ko) | 외용 소염진통제 | |
WO2013002196A1 (ja) | 新規医薬組成物 | |
NZ208693A (en) | Formulations of etofenamate:2-(2-hydroxyethoxy)-ethyl n-(alpha,alpha,alpha-trifluoro-m-tolyl)anthranilate | |
JPH0456802B2 (tr) | ||
IL303008A (en) | Tapinroff compositions in the form of gel, paste and foam and methods of their use | |
BR122023027784A2 (pt) | Preparação medicinal para uso externo | |
JPS5931709A (ja) | 9−(2−ヒドロキシエトキシメチル)グアニンを含有する浸透性局所製薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1997930461 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2258513 Country of ref document: CA Ref document number: 2258513 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09214055 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998/02769 Country of ref document: TR |
|
WWP | Wipo information: published in national office |
Ref document number: 1997930461 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997930461 Country of ref document: EP |